Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papilloguard4 versus Gardasil in healthy volunteers aged 15-25 years
IRCT20240120060741N1Phase 3Completed
- Sponsor
- Nivad Pharmed Salamat
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of qHPV vaccine in human papillomavirus infection and anogenital warts (2 arms), sponsored by Nivad Pharmed Salamat. Primary endpoints: HPV type 6 antibody geometric mean titer, HPV type 11 antibody geometric mean titer and 2 more. Started Apr 2024; status: completed.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionanogenital warts
Beyond the preview
Go deeper on IRCT20240120060741N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240120060741N1.